Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations

Thrombosis Research

Volumn 118, Issue 4, 2006, Pages 529-534

  Schwertner, H A ^a   McGlasson, D ^a   Christopher, M ^a   Bush, A C ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Aspirin; Formulations; Pharmacokinetics; Plasma concentrations; Platelet aggregation; Salicylic acid

Indexed keywords

ACETYLSALICYLIC ACID; SALICYLIC ACID;

ADULT; ARTICLE; CHEWABLE TABLET; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; ENTERIC COATED TABLET; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ARACHIDONIC ACID; ASPIRIN; CROSS-OVER STUDIES; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REFERENCE VALUES; SALICYLATES; SINGLE-BLIND METHOD; SOLUBILITY; TABLETS, ENTERIC-COATED; TIME FACTORS;

EID: 33748792814     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.10.001     Document Type: Article

References (21)

1. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2, ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2 (1988) 349-360
2. Lewis Jr. H.D., Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty III J.E., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309 (1983) 396-403
3. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
5. Goldman S., Copeland J., Moritz T., Henderson W., Zadina K., Ovitt T., Doherty J., et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77 (1988) 1324-1332
6. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 28 (1996) 1328-1428
7. Feldman M., and Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 84 (1999) 404-409
8. Friend M., Vucenik I., and Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326 (2003) 82-83
9. Cerletti C., Bonati M., del Maschio A., Gallettti F., Dejana E., Tognoni G., and del Gaetano G. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function. J Lab Clin Med 103 (1984) 869-877
10. Jakubowski J.A., Stampfer M.J., Vaillancourt R., and Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Hematol 60 (1985) 635-642
11. Dabaghi S.F., Kamat S.G., Payne J., Marks G.F., Roberts R., Schaefer A.I., et al. Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am J Cardiol 74 (1994) 720-723
12. Paccioretti M.J., and Block L.H. Effects of aspirin on platelet aggregation as a function of dosage and time. Clin Pharmacol Ther 27 (1980) 803-809
13. Ross-Lee L.M., Elms M.J., Cham B.E., Bochner F., Bunce I.H., and Eadie M.J. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. Eur J Clin Pharmacol 23 (1982) 545-551
14. Jimenez A.H., Stubbs M.E., Tofler G.H., Winther K., Williams G.H., and Muller J.E. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 69 (1992) 258-262
15. Siebert D.J., Bochner F., Imhoff D.M., Watts S., Lloyd J.V., Field J., et al. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 33 (1983) 367-374
16. Wilson K.M., Siebert D.M., Duncan E.M., Somogyi A.A., Lloyd J.V., and Bochner F. Effect of aspirin infusions on platelet function in humans. Clin. Sci. 79 (1990) 37-42
17. Bochner F., Williams D.B., Morris P.M., Siebert D.M., and Lloyd J.V. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Pharmacol 35 (1988) 287-294
18. Muir N., Nichols J.D., Stillings M.R., and Sykes J. Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Curr Med Res Opin 13 (1997) 491-500
19. Bochner F., Graham G.G., Cham B.E., Imhoff D.M., and Haavisto T.M. Salicylate metabolite kinetics after several salicylates. Clin Pharmacol Ther 30 (1981) 266-275
20. Brantmark B., Wahlin-Boll E., and Melander A. Bioavailability of acetylsalicylic acid and salicylic acid from rapid- and slow-release formulations, and in combination with dipyridamole. Eur J Clin Pharmacol 22 (1982) 309-314
21. Bochner F., Somogyi A.A., and Wilson K.M. Bioequivalence of four 100 mg oral aspirin formulations in healthy volunteers. Clin Pharmacokinet 21 (1991) 394-399